Sulfonylureas

Journal articles and book chapters

06-15-2019 | Bone health | Article

Analysis of fractures in patients with type 2 diabetes treated with empagliflozin in pooled data from placebo-controlled trials and a head-to-head study versus glimepiride

Kohler S et al. Diabetes Care 2018: dc171525. doi: 10.2337/dc17-1525

08-28-2018 | Oral combination medications | Article

Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: A systematic review and meta-analysis

Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

08-21-2018 | Dulaglutide | Article

Efficacy and safety of once‐weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulfonylurea: A 52‐week open‐label, randomized phase 3 trial

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

08-18-2018 | Medications | Article

Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: A network meta-analysis

Qian D et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0482-5

08-15-2018 | Type 2 diabetes | Article

Time to treatment intensification after monotherapy failure and its association with subsequent glycemic control among 93,515 patients with type 2 diabetes

Desai U et al. Diabetes Care 2018: dc170662. doi: 10.2337/dc17-0662

06-22-2018 | Monogenic diabetes | Review | Article

Advances in the genetics of youth-onset type 2 diabetes

Todd JN, Srinivasan S, Pollin TI. Curr Diab Rep 2018; 18: 57. doi: 10.1007/s11892-018-1025-1

06-22-2018 | Gastroparesis | Review | Article

Diabetic gastroparesis: Principles and current trends in management

Krishnasamy S, Abell TL. Diabetes Ther (2018); 9 (Suppl 1): 1. doi: 10.1007/s13300-018-0454-9

06-22-2018 | Monogenic diabetes | Review | Article

Monogenic diabetes in children and adolescents: Recognition and treatment options

Sanyoura M, Philipson LH, Naylor R. Curr Diab Rep 2018; 18: 58. doi: 10.1007/s11892-018-1024-2

06-21-2018 | Hypoglycemia | Review | Article

Hypoglycemia among patients with type 2 diabetes: Epidemiology, risk factors, and prevention strategies

Silbert R et al. Curr Diab Rep 2018; 18: 53. doi: 10.1007/s11892-018-1018-0

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-13-2018 | Neonatal diabetes | Review | Article

Congenital diabetes: Comprehensive genetic testing allows for improved diagnosis and treatment of diabetes and other associated features

Letourneau LR, Greeley SAW. Curr Diab Rep 2018; 18: 46. doi: 10.1007/s11892-018-1016-2

06-12-2018 | Empagliflozin | Article

Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

Balijepalli C et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0456-7

06-09-2018 | Cardiovascular disorders | Review | Article

Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA

Khat DZ, Husain M. Curr Diab Rep 2018; 18: 45. doi: 10.1007/s11892-018-1011-7

06-05-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

06-04-2018 | Neonatal diabetes | Article

Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: An international cohort study

Bowman P et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30106-2

06-01-2018 | DPP-4 inhibitors | Article

Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

Fadini GP et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0452-y

05-28-2018 | Sulfonylureas | Article

Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments

Powell WR, Christiansen CL, Miller DR. Diabetes Ther 2018. doi: 10.1007/s13300-018-0443-z

05-24-2018 | Gliclazide | Review | Article

The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents

Colagiuri S et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.05.028

05-22-2018 | Cardiovascular disorders | Article

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes

Matsutani D et al. Cardiovasc Diabetol 2018; 17: 73. doi: 10.1186/s12933-018-0717-9

05-19-2018 | Liraglutide (T2DM) | Article

Retrospective analysis of an insulin-to-liraglutide switch in patients with type 2 diabetes mellitus

Introduction: Insulin and the GLP-1 receptor agonist liraglutide are both effective in reaching glycemic targets. The efficacy of an insulin-to-liraglutide switch in an obese population with concurrent use of sulfonylurea and metformin is unknown. We assessed the efficacy and determinants of success of an insulin-to-liraglutide switch in these patients.